Evaluating the Safety of Gastrointestinal Contrast Agents in Pediatric Patients: A Retrospective Study
Our findings suggest that GI contrast agent exposure is generally safe in infants and does not increase the risk of NEC development within 30 days, including premature newborns. However, it may be safer to avoid hyperosmolar contrast agents in patients with active NEC.
Authors
- Tariq Altokhais
- Yasser AlFraih (ORCID: https://orcid.org/0000-0002-0749-3384)
- Abdullah Alshehri (ORCID: https://orcid.org/0000-0001-9968-1595)
- Mohammad Aldaffaa (ORCID: https://orcid.org/0000-0002-5787-7853)
- Rami Nassir (ORCID: https://orcid.org/0000-0001-9914-7851)
- Rayan Hejles
- Wassima Kaidali
Institutions
- Alfaisal University (SA)
- King Fahd Medical City (SA)
- King Saud University (SA)
- King Khalid University Hospital (SA)
- Sahyadri Hospital (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-11-25
- DOI
- https://doi.org/10.7759/cureus.97727
- Primary Topic
- Acute Kidney Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00